Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2013. The report details a specific share repurchase transaction executed on October 1, 2013, in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,445,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,561 pence per share; lowest price paid was 1,550.50 pence per share.
- Treasury Holdings (Settled): 481,189,412 shares (8.97% of total issued share capital).
- Treasury Holdings (Including Unsettled): 485,809,412 shares (9.95% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,884,440,483 shares.
Material Changes
The primary material change is the reduction of outstanding shares and the increase in treasury stock following the October 1, 2013, repurchase. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming adherence to the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (481,189,412 settled) against the company's latest capitalization table.
- Confirm the percentage of total voting rights held in Treasury (9.95% including unsettled shares) for proxy voting calculations.
- Check the total issued share capital excluding treasury shares (4,884,440,483) to ensure accurate denominator usage for ownership threshold notifications.